A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse

Neuroscience

Volumn 151, Issue 2, 2008, Pages 533-543

  Fantegrossi, W E ^a,d   Ciullo, J R ^b   Wakabayashi, K T ^c   De La Garza II, R ^e   Traynor, J R ^d   Woods, J H ^d  

^a EMORY UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

behavior; hyperthermia; MDMA; methamphetamine; mouse; neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENZODIAZEPINE RECEPTOR; CELL MARKER; DOPAMINE; METHAMPHETAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN REGION; CELL ACTIVATION; COGNITION; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTHERMIA; INJECTION; LOCOMOTION; MALE; MEASUREMENT; MICROGLIA; MOUSE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TELEMETRY; WEIGHT REDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BODY WEIGHT; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; DATA INTERPRETATION, STATISTICAL; DOPAMINE; HALLUCINOGENS; ISOQUINOLINES; MALE; METHAMPHETAMINE; MICE; MICROGLIA; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEOSTRIATUM;

EID: 37849045276     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.11.007     Document Type: Article

References (36)

1. Benavides J., Fage D., Carter C., and Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res 421 1-2 (1987) 167-172
2. Bowyer J.F., Tank A.W., Newport G.D., Slikker Jr. W., Ali S.F., and Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260 2 (1992) 817-824
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
4. Casellas P., Galiegue S., and Basile A.S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 40 (2002) 475-486
5. Chipana C., Camarasa J., Pubill D., and Escubedo E. Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 51 4 (2006) 885-895
6. Colado M.I., O'Shea E., and Green A.R. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology 173 (2004) 249-263
7. DeSouza E.B., Battaglia G., and Insel T.R. Neurotoxic effects of MDMA on brain serotonin neurons: evidence from neurochemical and radioligand binding studies. Ann N Y Acad Sci 600 (1990) 682-698
8. Easton N., and Marsden C.A. Ecstasy: are animal data consistent between species and can they translate to humans?. J Psychopharmacol 20 2 (2006) 194-210
9. Escubedo E., Guitart L., Sureda F.X., Jiménez A., Pubill D., Pallàs M., Camins A., and Camarasa J. Migrogliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res 814 (1998) 120-126
10. Gibb J.W., Johnson M., Stone D., and Hanson G.R. MDMA: Historical perspectives. Ann N Y Acad Sci 600 (1990) 601-612
11. Gibb J.W., Hanson G.R., and Johnson M. Neurochemical mechanisms of toxicity. In: Cho A.K., and Segal D.S. (Eds). Amphetamine and its analogues: psychopharmacology, toxicity, and abuse (1994), Academic Press Inc, San Diego 269-295
12. Grob C.S. Deconstructing ecstasy: the politics of MDMA research. Addict Res 8 (2000) 549-588
13. Harvey J.A., McMaster S.E., and Yunger L.M. p-Chloroamphetamine: Selective neurotoxic action in brain. Science 187 (1975) 841-843
14. Kalia M. Do validated biological measures of neurotoxicity really support the claim that MDMA is neurotoxic to man?. Neuropsychobiology 42 (2000) 45
15. Kish S.J. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?. Pharmacol Biochem Behav 71 (2002) 845-855
16. Liechti M.E., Gamma A., and Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology 154 2 (2001) 161-168
17. Malberg J.E., and Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18 13 (1998) 5086-5094
18. Milani R.M., Parrott A.C., Turner J.J., and Fox H.C. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav 29 5 (2004) 965-971
19. Miller D.B., and O'Callaghan J.P. The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol 11 1-3 (1995) 177-192
20. O'Callaghan J.P., and Miller D.B. Quantification of reactive gliosis as an approach to neurotoxicity assessment. NIDA Res Monogr 136 (1993) 188-212
21. O'Callaghan J.P., and Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270 2 (1994) 741-751
22. Palenicek T., Votava M., Bubenikova V., and Horacek J. Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 86 4 (2005) 546-553
23. Papadopoulos V., Lecanu L., Brown R.C., Han Z., and Yao Z.X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138 (2006) 749-756
24. Park C.H., Carboni E., Wood P.L., and Gee K.W. Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia 16 1 (1996) 65-70
25. Pletscher A., Burkard W.P., Bruderer H., and Gey K.F. Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindoleacetic acid by arylalkylamine. Life Sci 11 (1963) 828-833
26. Pletscher A., Bartholini G., Bruderer H., Burkard W.P., and Gey K.F. Chlorinated arylalkylamines affecting the cerebral metabolism of 5-hydroxytryptamine. J Pharmacol Exp Ther 145 (1964) 344-350
27. Pubill D., Canudas A.M., Pallàs M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 490-499
28. Ricaurte G.A., Yuan J., and McCann U.D. (+/-)-Methylenedioxymethamphetamine (MDMA, "ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42 (2000) 5-10
29. Sanders-Bush E., and Sulser F. P-chloroamphetamine: in vivo investigations on the mechanism of action of the selective depletion of cerebral serotonin. J Pharmacol Exp Ther 175 2 (1970) 419-426
30. Sprague J.E., Everman S.L., and Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 3 (1998) 427-441
31. Stephenson D.T., Schober D.A., Smalstig E.B., Mincy R.E., Gehlert D.R., and Clemens J.A. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci 15 7 Pt 2 (1995) 5263-5274
32. Streit W.J., and Graeber M.B. Heterogeneity of microglial and perivascular cell populations: insights gained from the facial nucleus paradigm. Glia 7 1 (1993) 68-74
33. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., and Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367 3 (2004) 349-354
34. Venneti S., Lopresti B.J., and Wiley C.A. The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 80 6 (2006) 308-322
35. Verheyden S.L., Hadfield J., Calin T., and Curran H.V. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences. Psychopharmacology 161 1 (2002) 23-31
36. Wang X., Baumann M.H., Xu H., and Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53 4 (2004) 240-248